The use of fluoroquinolones in gonorrhoea: The increasing problem of resistance

Michael Dan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The recent re-emergence of gonorrhoea in developed countries has been accompanied by the rise and spread of gonococcal resistance to the fluoroquinolones. In the 1980s fluoroquinolones were considered an important addition to the arsenal of agents used to treat gonorrhoea. They proved to be excellent drugs for this indication, including infections caused by penicillinase-producing and tetracycline-resistant strains of Neisseria gonorrhoeae. However, as gonococci have a well-recognised potential to develop resistance to antibiotics, the first reports of reduced susceptibility to fluoroquinolones appeared a few years after their introduction. Gonococcal resistance to fluoroquinolones is now well-established in the Far East, from where it has spread to Australia, Hawaii, California and Europe. In Africa and Latin America, gonococci continue to be susceptible to fluoroquinolones. 2004

Original languageEnglish
Pages (from-to)829-854
Number of pages26
JournalExpert Opinion on Pharmacotherapy
Issue number4
StatePublished - Apr 2004
Externally publishedYes


  • Ciprofloxacin
  • DNA gyrase
  • DNA topoisomerase
  • Drug resistance
  • Fluoroquinolones
  • Gonorrhoea
  • Neisseria gonorrhoeae


Dive into the research topics of 'The use of fluoroquinolones in gonorrhoea: The increasing problem of resistance'. Together they form a unique fingerprint.

Cite this